Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899986 | 0.89 | PTPN1 (0.34) | PTGS2PTPN1PTPN2MAPK8MAPK9 | |
| SCHEMBL4903141 | 0.88 | NR1H2 (0.34) | PTGS2PTPN1NR1H2 | |
| SCHEMBL4899373 | 0.88 | PTPN1 (0.44) | PTGS2PTPN1NR1H2GCGRPTPN2 | |
| SCHEMBL4900094 | 0.85 | SDHB (0.34) | PTGS2PTPN1NR1H2 | |
| SCHEMBL4897222 | 0.85 | NOTUM (0.38) | MAPK8MAPK10 | |
| SCHEMBL4901292 | 0.84 | PTPN1 (0.33) | PTGS2PTPN1NR1H2GCGRPTPN2 | |
| SCHEMBL4901615 | 0.83 | KMT2A (0.38) | PTGS2NR1H2 | |
| SCHEMBL14257193 | 0.83 | GCGR (0.34) | PTGS2PTPN1NR1H2GCGRPTPN2 | |
| SCHEMBL4901609 | 0.82 | MKNK1 (0.37) | PTGS2MAPK8MAPK9MAPK10 | |
| SCHEMBL4894169 | 0.81 | NR1H2 (0.36) | PTGS2PTPN1NR1H2PTPN2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PTGS2 1384/4885PTPN1 13/4885NR1H2 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.